New Brain Cancer Drug GLIX1 Enters Human Trials With Novel DNA Attack

OSLO, Norway – April 08, 2026 – In a significant development for neuro-oncology, clinical-stage company Hemispherian AS has announced the initiation of a first-in-human clinical trial for GLIX1, a novel therapeutic candidate for glioblastoma (GBM), the most aggressive and lethal form of brain cancer. The Phase 1/2a study brings a new mechanism of action to the forefront of a field desperately in need of innovation, offering a potential beacon of hope for patients with recurrent and progressive high-grade gliomas.

The trial, conducted in collaboration with BioLineRx Ltd., marks the culmination of years of dedicated research into the fundamental vulnerabilities of cancer cells. It will evaluate the safety and efficacy of GLIX1, an orally available small molecule that represents a completely new strategy for targeting an otherwise intractable disease.

A Novel Weapon Against an Intractable Foe

Glioblastoma is notorious for its resistance to conventional therapies. The current standard of care—a combination of surgery, radiation, and chemotherapy with temozolomide—has only incrementally improved patient survival over decades, with a median prognosis of just 12 to 15 months. The disease's profound resilience stems from its genetic complexity and the protective blood-brain barrier, which prevents many drugs from reaching the tumor.

GLIX1 aims to bypass these challenges with a unique and highly targeted mechanism. The drug is designed to activate an enzyme called TET2, a critical tumor suppressor. In many cancers, including glioblastoma, TET2 activity is significantly suppressed. GLIX1 works by restoring this activity, which in turn triggers a cascade of events that leads to DNA damage selectively within cancer cells, causing them to self-destruct while leaving healthy cells unharmed.

“GLIX1 is built on a fundamentally new understanding of how to exploit DNA repair vulnerabilities in cancer,” said Adam Robertson, Chief Scientific Officer at Hemispherian. “The strength and consistency of the preclinical data give us confidence as we now transition this mechanism into the clinic.”

This approach is a paradigm shift from many other cancer therapies. Instead of blocking DNA repair pathways, GLIX1 actively induces damage by leveraging the tumor's own epigenetic weaknesses. Extensive preclinical studies have validated this strategy, showing that GLIX1 demonstrates potent anti-tumor activity and, crucially, can effectively cross the blood-brain barrier. Furthermore, toxicology studies have indicated a favorable safety profile, paving the way for this pivotal human trial.

Strategic Alliance Targets a High-Need Market

The initiation of the GLIX1 trial is not only a scientific milestone but also a significant strategic move for Hemispherian. The Oslo-based company, in partnership with BioLineRx through a joint venture named Tetragon Biosciences, is stepping into one of the most challenging areas of oncology. The decision to target glioblastoma first underscores the company's confidence in GLIX1's mechanism, as this cancer's suppressed TET2 activity makes it an ideal initial indication.

Recognizing the critical unmet need, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted GLIX1 Orphan Drug Designation. This status is reserved for therapies targeting rare diseases and provides significant incentives, including market exclusivity upon approval, to encourage development for patient populations with few or no treatment options.

“The initiation of this Phase 1/2a study marks a defining milestone for Hemispherian and represents the culmination of years of dedicated research and development work by our team and our collaboration partner, BioLineRx,” stated Zeno Albisser, Chief Executive Officer of Hemispherian AS. “GLIX1 has a compelling preclinical profile and a truly differentiated mechanism of action, and we look forward to bringing this innovative therapy to patients who urgently need new treatment options.”

A Coalition of Experts Launches Landmark Trial

To ensure the highest standards of clinical research, the GLIX1 trial (NCT07464925) is being conducted across three of the world's most prestigious academic cancer centers. This collaboration brings together leading minds in neuro-oncology to rigorously evaluate the potential of this first-in-class molecule.

The first site to begin enrolling patients is NYU Langone Health's Perlmutter Cancer Center, led by Dr. Alexandra Miller, Chief of Neuro-Oncology. “I am pleased to be the first investigator able to enroll patients into this critical study, which brings new hope to patients who are in desperate need of innovative and novel treatment options,” Dr. Miller commented.

Joining the effort are Northwestern University and the Moffitt Cancer Center. The trial at Northwestern is notably led by Dr. Roger Stupp, a luminary in the field whose name is synonymous with the current standard-of-care protocol for glioblastoma. His involvement lends immense credibility to the study.

“GLIX1 is a promising innovative molecule with impressive pre-clinical data, and I could not be more excited to participate in this study,” said Dr. Stupp. “The protocol will rigorously assess the safety of an agent with an entirely novel mechanism of action, with the potential to ultimately integrate well and synergize with the current treatments. We urgently need breakthrough innovations for our patients suffering from glioblastoma, one of the most aggressive and difficult malignancies to treat.”

Additional investigators include Dr. Ditte Primdahl at Northwestern University and Dr. Patrick Grogan at Moffitt Cancer Center, forming a powerful consortium dedicated to advancing glioblastoma treatment.

Charting the Course: Trial Design and Future Directions

The Phase 1 portion of the study is designed to enroll up to 30 patients with recurrent and progressive glioblastoma and other high-grade gliomas. Its primary goal is to determine the maximum tolerated dose (MTD) of GLIX1 and establish a recommended dose for further studies. This phase will meticulously monitor safety, pharmacokinetics (how the drug moves through the body), and pharmacodynamics (the drug's effect on the body), while also looking for preliminary signs of efficacy. Hemispherian anticipates an initial data readout from this phase in the first half of 2027.

Following the dose-escalation phase, the study will advance to a Phase 2a expansion. This part of the trial is designed to generate early efficacy signals in more specific patient groups. It is expected to include multiple cohorts, evaluating GLIX1 in both newly diagnosed and recurrent GBM patients. The expansion will also explore the drug's potential in other tumor types that may share similar vulnerabilities.

Significantly, the Phase 2a design includes plans to evaluate GLIX1 in combination with other therapies, such as PARP inhibitors, which could create a synergistic effect and further enhance anti-tumor activity. These carefully designed cohorts will provide crucial data to inform dose optimization and guide the subsequent stages of clinical development, moving this promising new therapy one step closer to the patients who need it most.